Definitely will be an interesting comparison to make over the coming months and years. NRT definitely impressive invitro and mice with a number of different trials in pipeline.
PAA in front in so far as time from market with animal product, but also behind, as still more work needed with respect to individual cancer targets for humans.
Both companies have a broad spectrum of targets, both novel approaches.
One thing that PAA does have is 'ownership' of the entire class of drugs/applications - PAA has the entire space so to speak
The Quiet Achiever, page-24
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 135256 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 79851 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |